Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $16.02, but opened at $21.10. Maze Therapeutics shares last traded at $24.42, with a volume of 1,030,535 shares trading hands.
Analyst Ratings Changes
MAZE has been the subject of a number of recent research reports. Wedbush initiated coverage on Maze Therapeutics in a research note on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 target price for the company. Wall Street Zen raised Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. HC Wainwright began coverage on Maze Therapeutics in a report on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 price target for the company. Finally, BTIG Research began coverage on Maze Therapeutics in a report on Tuesday, September 2nd. They issued a "buy" rating and a $30.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $26.33.
Get Our Latest Analysis on Maze Therapeutics
Maze Therapeutics Trading Up 44.1%
The business has a fifty day simple moving average of $14.78 and a 200 day simple moving average of $12.09.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.
Institutional Trading of Maze Therapeutics
Several hedge funds have recently made changes to their positions in MAZE. New York State Common Retirement Fund bought a new stake in shares of Maze Therapeutics in the 1st quarter worth approximately $25,000. CWM LLC bought a new stake in shares of Maze Therapeutics in the 2nd quarter worth approximately $28,000. Corebridge Financial Inc. bought a new stake in shares of Maze Therapeutics in the 1st quarter worth approximately $48,000. Legal & General Group Plc lifted its holdings in shares of Maze Therapeutics by 387.0% in the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock worth $52,000 after purchasing an additional 3,371 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Maze Therapeutics by 452.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock worth $57,000 after purchasing an additional 3,774 shares during the last quarter.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
